[go: up one dir, main page]

DE60141234D1 - Soluble cytokine receptor zalpfa11 - Google Patents

Soluble cytokine receptor zalpfa11

Info

Publication number
DE60141234D1
DE60141234D1 DE60141234T DE60141234T DE60141234D1 DE 60141234 D1 DE60141234 D1 DE 60141234D1 DE 60141234 T DE60141234 T DE 60141234T DE 60141234 T DE60141234 T DE 60141234T DE 60141234 D1 DE60141234 D1 DE 60141234D1
Authority
DE
Germany
Prior art keywords
methods
zalpfa11
vitro
vivo
cytokine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141234T
Other languages
German (de)
Inventor
Cindy A Sprecher
Julia E Novak
James W West
Scott R Presnell
Richard D Holly
Andrew J Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DE60141234D1 publication Critical patent/DE60141234D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonist, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
DE60141234T 2000-04-05 2001-04-03 Soluble cytokine receptor zalpfa11 Expired - Lifetime DE60141234D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19473100P 2000-04-05 2000-04-05
US22212100P 2000-07-28 2000-07-28

Publications (1)

Publication Number Publication Date
DE60141234D1 true DE60141234D1 (en) 2010-03-18

Family

ID=26890341

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60125543T Expired - Lifetime DE60125543T2 (en) 2000-04-05 2001-04-03 SOLUBLE CYTOKINE RECEPTOR ZALPHA11
DE60141234T Expired - Lifetime DE60141234D1 (en) 2000-04-05 2001-04-03 Soluble cytokine receptor zalpfa11

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60125543T Expired - Lifetime DE60125543T2 (en) 2000-04-05 2001-04-03 SOLUBLE CYTOKINE RECEPTOR ZALPHA11

Country Status (9)

Country Link
US (9) US6777539B2 (en)
EP (2) EP1749888B1 (en)
AT (2) ATE349522T1 (en)
AU (1) AU2001253127A1 (en)
CA (1) CA2420992C (en)
DE (2) DE60125543T2 (en)
DK (2) DK1749888T3 (en)
ES (2) ES2339959T3 (en)
WO (1) WO2001077171A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2237915A1 (en) * 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
DK1749888T3 (en) * 2000-04-05 2010-05-10 Zymogenetics Inc Soluble Zalph11a cytokine receptors
PT1353953E (en) * 2000-05-11 2007-02-28 Genetics Inst Llc Mu-1, member of the cytokine receptor family
ATE540575T1 (en) * 2001-03-16 2012-01-15 Basf Plant Science Gmbh REGULATORS OF SUGAR AND LIPID METABOLISM IN PLANTS
CA2460916A1 (en) * 2001-10-04 2003-04-10 Laura Carter Methods and compositions for modulating interleukin-21 receptor activity
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
EP2380633A1 (en) 2002-06-07 2011-10-26 ZymoGenetics, Inc. Use of IL-21 in cancer
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
JP4776228B2 (en) 2002-07-15 2011-09-21 ワイス・エルエルシー Methods and compositions for modulating the development and function of T helper (TH) cells
CN102040662A (en) * 2003-03-14 2011-05-04 惠氏有限责任公司 Antibodies against human IL-21 receptor and uses therefor
WO2004084835A2 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
DK1692276T3 (en) * 2003-11-19 2010-11-01 Us Gov Health & Human Serv Method for Induction of Development and Terminal Differentiation of Memory B Cells
BRPI0510996A (en) * 2004-05-19 2007-12-04 Wyeth Corp methods for ameliorating a symptom of an atopic disorder, and for treating or preventing an atopic disorder in a patient, methods for modulating igg and ige production in a cell, and relative levels of ige and igg, pharmaceutical composition, container, methods for evaluate a patient having or suspected of having an atopic disorder, and to assess a patient for the risk of an atopic disorder
CN102188704B (en) 2004-05-20 2013-04-24 津莫吉尼蒂克斯公司 Methods of treating cancer using IL-21 and monoclonal antibody therapy
WO2006135385A2 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
JP2008515434A (en) * 2004-10-08 2008-05-15 ジョージア テック リサーチ コーポレイション Microencapsulation of cells in hydrogels using electrostatic potential
GT200600148A (en) * 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
JP2009532680A (en) * 2006-03-31 2009-09-10 フェラーニ−カイル，カリマ Methods and compositions for obtaining and using bioactive multiprotein complexes
JP5745274B2 (en) * 2007-12-07 2015-07-08 ザイモジェネティクス， インコーポレイテッド Anti-human IL-21 monoclonal antibody
JP2011520989A (en) * 2008-05-23 2011-07-21 ワイス・エルエルシー Therapeutic method using interleukin-21 receptor binding protein
PE20100141A1 (en) * 2008-05-23 2010-02-22 Wyeth Corp BINDING PROTEIN TO THE INTERLEUQUIN RECEPTOR 21
WO2010044472A1 (en) 2008-10-16 2010-04-22 Ｈｏｙａ Ｃａｎｄｅｏ Ｏｐｔｒｏｎｉｃｓ株式会社 Polarizing glass and optical isolator
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CA2810129A1 (en) * 2010-09-03 2012-03-08 Confarma France Quantification of residual host cell dna by real-time quantitative pcr
CA2824143C (en) 2011-01-14 2018-12-18 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING SAME
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
US12421288B2 (en) 2023-03-16 2025-09-23 A-Alpha Bio Interferon alpha-2 variants
WO2025038726A2 (en) * 2023-08-14 2025-02-20 A-Alpha Bio Interleukin 21 variants

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
AU5733898A (en) 1997-01-16 1998-08-07 Genetics Institute Inc. Member of the hematopoietin receptor superfamily
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2330547A1 (en) 1998-06-24 1999-12-29 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor proteins
AU5104799A (en) 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
EA006501B1 (en) 1998-09-23 2005-12-29 Займодженетикс, Инк. Human cytokine receptor zalpha 11 polypeptides of class i, polynucleotides encoding them and methods for their use
CN1335836A (en) 1998-11-06 2002-02-13 巴斯福股份公司 Tricyclic pyrazole derivatives
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) * 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
DK1749888T3 (en) * 2000-04-05 2010-05-10 Zymogenetics Inc Soluble Zalph11a cytokine receptors

Also Published As

Publication number Publication date
US6777539B2 (en) 2004-08-17
US7763713B2 (en) 2010-07-27
DE60125543D1 (en) 2007-02-08
ATE456654T1 (en) 2010-02-15
DK1303602T3 (en) 2007-05-07
US20080032333A1 (en) 2008-02-07
EP1749888A3 (en) 2007-03-14
EP1749888A2 (en) 2007-02-07
US20110003973A1 (en) 2011-01-06
WO2001077171A2 (en) 2001-10-18
ES2339959T3 (en) 2010-05-27
EP1749888B1 (en) 2010-01-27
US20100074905A1 (en) 2010-03-25
US20090196882A1 (en) 2009-08-06
DK1749888T3 (en) 2010-05-10
US20040235743A1 (en) 2004-11-25
EP1303602B1 (en) 2006-12-27
US7629452B2 (en) 2009-12-08
CA2420992C (en) 2010-07-13
US20110189207A1 (en) 2011-08-04
AU2001253127A1 (en) 2001-10-23
EP1303602A2 (en) 2003-04-23
US20070224118A1 (en) 2007-09-27
US7189695B2 (en) 2007-03-13
DE60125543T2 (en) 2007-10-04
US20020137677A1 (en) 2002-09-26
ES2279809T3 (en) 2007-09-01
CA2420992A1 (en) 2001-10-18
ATE349522T1 (en) 2007-01-15
WO2001077171A3 (en) 2002-05-16
US20090221802A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
ATE456654T1 (en) SOLUBLE CYTOKINE RECEPTOR ZALPFA11
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
IL163067A (en) Isolated heterodimeric cytokine receptor
DK1356046T3 (en) Cytokine receptor zcytoR19
WO2002000721A3 (en) Cytokine receptor zcytor17
UA84387C2 (en) Human cytokine as a ligand of zalpha receptor and use thereof
DE69738066D1 (en) HEMATOPOIETIC CYTOKINE RECEPTOR
NZ510744A (en) Cytokine receptor zalpha11
PT1066380E (en) T SOLUVEL CELL RECEIVER
OA09704A (en) Antibody antagonist of human interleukin-4.
DK0759942T3 (en) Interleukin-15 receptors
WO2003089603A3 (en) Cytokine receptor
TR199901636T2 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin bound antibodies as therapeutic agents for the treatment of immunological diseases .
HU9300900D0 (en) Human gamma-interferon antagonists
DE69529674D1 (en) BIOLOGICALLY ACTIVE LIGANDS OF THE EPH FAMILY
EP1736545A3 (en) Soluble zcytor 11 cytokine receptors
WO1992016623A3 (en) Receptors for bombesin-like peptides
UA84540C2 (en) Novel cytokine zcytor17 ligand

Legal Events

Date Code Title Description
8364 No opposition during term of opposition